Celcuity (CELC) Competitors $10.60 -0.05 (-0.47%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$10.79 +0.19 (+1.78%) As of 05/21/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CELC vs. GRAL, TDOC, AHCO, AVAH, VRDN, PNTG, CDNA, AGL, FLGT, and INNVShould you be buying Celcuity stock or one of its competitors? The main competitors of Celcuity include Grail (GRAL), Teladoc Health (TDOC), AdaptHealth (AHCO), Aveanna Healthcare (AVAH), Viridian Therapeutics (VRDN), The Pennant Group (PNTG), CareDx (CDNA), agilon health (AGL), Fulgent Genetics (FLGT), and InnovAge (INNV). These companies are all part of the "healthcare" industry. Celcuity vs. Grail Teladoc Health AdaptHealth Aveanna Healthcare Viridian Therapeutics The Pennant Group CareDx agilon health Fulgent Genetics InnovAge Celcuity (NASDAQ:CELC) and Grail (NASDAQ:GRAL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation. Does the MarketBeat Community prefer CELC or GRAL? Celcuity received 341 more outperform votes than Grail when rated by MarketBeat users. Likewise, 67.92% of users gave Celcuity an outperform vote while only 33.33% of users gave Grail an outperform vote. CompanyUnderperformOutperformCelcuityOutperform Votes34367.92% Underperform Votes16232.08% GrailOutperform Votes233.33% Underperform Votes466.67% Does the media prefer CELC or GRAL? In the previous week, Celcuity had 3 more articles in the media than Grail. MarketBeat recorded 19 mentions for Celcuity and 16 mentions for Grail. Grail's average media sentiment score of 1.18 beat Celcuity's score of 0.90 indicating that Grail is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Grail 12 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CELC or GRAL more profitable? Grail's return on equity of 0.00% beat Celcuity's return on equity.Company Net Margins Return on Equity Return on Assets CelcuityN/A -62.66% -39.78% Grail N/A N/A N/A Do insiders & institutionals have more ownership in CELC or GRAL? 63.3% of Celcuity shares are held by institutional investors. 15.8% of Celcuity shares are held by insiders. Comparatively, 1.9% of Grail shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend CELC or GRAL? Celcuity currently has a consensus target price of $30.80, indicating a potential upside of 190.57%. Grail has a consensus target price of $31.50, indicating a potential downside of 15.91%. Given Celcuity's stronger consensus rating and higher possible upside, analysts clearly believe Celcuity is more favorable than Grail.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celcuity 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Grail 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has preferable valuation & earnings, CELC or GRAL? Celcuity has higher earnings, but lower revenue than Grail. Celcuity is trading at a lower price-to-earnings ratio than Grail, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelcuityN/AN/A-$63.78M-$3.03-3.50Grail$130.71M10.31-$2.19B-$60.99-0.61 SummaryCelcuity beats Grail on 11 of the 16 factors compared between the two stocks. Get Celcuity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CELC vs. The Competition Export to ExcelMetricCelcuityMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$401.09M$2.92B$5.37B$8.39BDividend YieldN/A31.24%5.22%4.10%P/E Ratio-4.0612.8626.8419.71Price / SalesN/A160.59392.34117.39Price / CashN/A57.5638.2534.62Price / Book1.934.276.794.50Net Income-$63.78M-$22.21M$3.23B$248.18M7 Day Performance0.76%1.91%1.53%0.20%1 Month Performance-4.68%2.20%10.06%12.37%1 Year Performance-33.71%1.41%16.72%7.04% Celcuity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELCCelcuity2.1157 of 5 stars$10.60-0.5%$30.80+190.6%-35.8%$401.09MN/A-4.0640Trending NewsAnalyst ForecastAnalyst RevisionGRALGrail0.7905 of 5 stars$38.23-4.2%$31.50-17.6%N/A$1.44B$130.71M-0.631,360Positive NewsGap DownTDOCTeladoc Health3.6814 of 5 stars$7.31-2.8%$9.71+32.8%-40.9%$1.28B$2.55B-1.275,100Positive NewsAnalyst RevisionGap DownAHCOAdaptHealth2.3159 of 5 stars$8.99-0.3%$13.40+49.1%-7.2%$1.21B$3.25B-5.4510,900AVAHAveanna Healthcare0.7273 of 5 stars$5.70-4.8%$5.13-10.1%+88.0%$1.11B$2.09B-16.7633,000Insider TradeHigh Trading VolumeVRDNViridian Therapeutics2.5242 of 5 stars$12.82-0.9%$36.70+186.3%+6.1%$1.06B$302,000.00-2.9750Positive NewsAnalyst ForecastPNTGThe Pennant Group2.8101 of 5 stars$29.74-1.6%$35.60+19.7%+20.9%$1.03B$748.17M43.745,340Positive NewsGap UpCDNACareDx3.6555 of 5 stars$17.70+0.9%$30.33+71.4%+12.7%$985.55M$346.42M-6.56740Gap UpAGLagilon health1.9247 of 5 stars$2.33-4.9%$4.90+110.3%-57.6%$964.51M$5.99B-2.48650FLGTFulgent Genetics3.9841 of 5 stars$21.22+4.3%$24.00+13.1%-5.3%$646.02M$292.45M-3.841,010News CoveragePositive NewsINNVInnovAge1.0529 of 5 stars$4.19flat$5.00+19.3%-9.5%$565.70M$831.68M-22.052,000 Related Companies and Tools Related Companies Grail Competitors Teladoc Health Competitors AdaptHealth Competitors Aveanna Healthcare Competitors Viridian Therapeutics Competitors The Pennant Group Competitors CareDx Competitors agilon health Competitors Fulgent Genetics Competitors InnovAge Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CELC) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celcuity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celcuity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CELC Stock Free CELC Stock Alerts